MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Rigel Pharmaceuticals Net Income 2011-2026 | RIGL
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Rigel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 367 M | 17.5 M | -25.1 M | -58.6 M | -17.9 M | -29.7 M | -66.9 M | -70.5 M | -78 M | -69.2 M | -51.5 M | -90.9 M | -89 M | -98.8 M | -86 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 367 M | -98.8 M | -29.8 M |
Quarterly Net Income Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.9 M | 59.6 M | 11.4 M | 12.4 M | -1.03 M | -8.25 M | -5.69 M | -6.6 M | -13.5 M | - | -19 M | -13.5 M | -27.4 M | - | -21 M | -13.8 M | 39.5 M | -19.2 M | -14.2 M | 3.67 M | 21.2 M | -17.2 M | -49.7 M | -38.2 M | -17.6 M | 3.23 M | -73.7 M | -49.9 M | -24.4 M | -25.9 M | -52.1 M | -34.5 M | -15.3 M | -15.6 M | -53.6 M | -31 M | -17.5 M | -12.7 M | -6.67 M | -13.9 M | -18.2 M | -22.3 M | -20.9 M | -25.4 M | -22.3 M | -16.9 M | -23.8 M | -22.8 M | -25.6 M | -25.5 M | -25.5 M | -24.7 M | -23.2 M | -25.8 M | -17.9 M | -21.5 M | -20.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.6 M | -73.7 M | -16.7 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
-20.2 M | $ 0.8 | 2.7 % | $ 133 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Altimmune
ALT
|
-88.1 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 218.06 | -1.72 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Incyte Corporation
INCY
|
1.29 B | $ 90.45 | -0.36 % | $ 17.7 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-135 M | $ 1.61 | 1.9 % | $ 35.7 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Inventiva S.A.
IVA
|
-49.6 M | $ 6.08 | 5.19 % | $ 138 M | France |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-220 M | $ 12.84 | 0.78 % | $ 774 M | USA |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
KalVista Pharmaceuticals
KALV
|
-183 M | $ 16.6 | -2.35 % | $ 824 M | Britain |
 |
Kamada Ltd.
KMDA
|
-2.23 M | $ 8.2 | -0.61 % | $ 260 M | Israel |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-119 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | USA |
 |
Karyopharm Therapeutics
KPTI
|
-76.4 M | $ 6.66 | -12.71 % | $ 812 K | USA |
 |
Keros Therapeutics
KROS
|
87 M | $ 11.24 | 2.55 % | $ 418 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-265 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Longeveron
LGVN
|
-22.7 M | $ 0.95 | -2.71 % | $ 16.7 B | USA |
 |
Denali Therapeutics
DNLI
|
-423 M | $ 21.09 | 4.56 % | $ 3.47 B | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-72.8 M | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |